You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health, behavioural and neurodevelopmental conditions
  5. Psychosis and schizophrenia

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

  • Technology appraisal guidance
  • Reference number: TA213
  • Published:  26 January 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submissions
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Appraisal committee members, guideline representatives and NICE project team
  • 7 Sources of evidence considered by the committee
  • Update information

Update information

Minor changes since publication

February 2014: Implementation section updated to clarify that aripiprazole is recommended as an option for treating schizophrenia.

ISBN: 978-1-4731-5625-8


Previous page 7 Sources of evidence considered by the committee
Back to top